title: A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder.
abstract: OBJECTIVE
  Surveillance protocols after radical surgery for genitourinary tumors typically do not consider that the risk of recurrence is stage dependent. We describe the development of a stage specific protocol for monitoring patients with transitional cell carcinoma for tumor recurrence and conduit complications after radical cystectomy.
  
  
  METHODS
  The records of 382 patients with transitional cell carcinoma who underwent cystectomy in 1986 to 1994 were reviewed for the dates and presenting symptoms of local and distant recurrences, and the results of radiological imaging studies and liver function tests. Based on the division of patients into pathological stages of pT1, pT2 and pT3 groups, we developed a new transitional cell carcinoma surveillance protocol.
  
  
  RESULTS
  Of 97 patients with transitional cell carcinoma metastases 72 (74%) were asymptomatic, including 43 with metastases detected by routine chest x-rays (30) or blood tests (13). Surveillance computerized tomography identified isolated asymptomatic intra-abdominal metastases in 10 patients (10%), of whom 90% had pT3 disease. Based on these results we recommend a stage specific surveillance protocol for pT1--annual history, physical examination, chest x-ray and laboratory studies, pT2-same studies at 6, 12, 18, 24, 30, 36, 48 and 60 months after cystectomy, and pT3-same studies at 3, 6, 12, 18, 24, 30, 36, 48 and 60 months plus computerized tomography at 6, 12 and 24 months after cystectomy. A radiographic study of the upper tract should be performed in all patients every 1 to 2 years to evaluate for recurrences and complications of the ileoureteral anastomosis.
  
  
  CONCLUSIONS
  A stage driven surveillance strategy for monitoring patients after radical cystectomy can reduce costly imaging studies while efficiently detecting recurrences and complications.
authors.affiliation: Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Slaton
authors.forename: D A
authors.initials: DA
authors.lastname: Swanson
authors.forename: H B
authors.initials: HB
authors.lastname: Grossman
authors.forename: C P
authors.initials: CP
authors.lastname: Dinney
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000556:secondary / Q000601:surgery*; D002985:Clinical Protocols; D015653:Cystectomy; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D011159:Population Surveillance; D012189:Retrospective Studies; D013997:Time Factors; D014516:Ureteral Neoplasms / Q000556:secondary*; D014523:Urethral Neoplasms / Q000556:secondary*; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000601:surgery*